Active substance (dermatological)
Definition
This section has been translated automatically.
Substances used in magistral prescriptions or finished preparations for external therapy (see also excipient).
Classification
This section has been translated automatically.
- Overview of the cationic active substances used in magistral formulations or finished preparations for external therapy and their allocation to active substance classes:
- antibiotics:
- Chlortetracycline-HCl
- Clindamycin dihydrogen phosphate
- Framycetin sulfate
- Gentamicin sulphate
- Neomycin sulfate
- Oxytetracycline-HCl
- Tetracycline-HCl
- Antifungals:
- Antiseptics:
- Benzalkonium Chloride
- Chlorhexidine digluconate
- Dequalinium chloride
- Ethacridine lactate
- Hydroxyquinoline sulfate
- Methylrosanilinium chloride
- Antihistamines:
- Bamipine HCl
- Bromopheniramine hydrogen maleate
- Chlorphenoxamine-HCl
- Dimetine maleate
- Diphenhydramine HCl
- Doxepin-HCl
- Pheniramine hydrogen maleate
- Local anaesthetics:
- Other:
- Aluminium Chloride Hexahydrate
- Diltiazem-HCl.
- Overview of the surfactants used in magistral formulations or finished preparations for external therapy:
- antihistamines:
- Benzalkonium chloride
- coal tar solution and coal spirit
- Ichthyol/Lightkichthol
- Local anaesthetics:
- Overview of the anionic agents used in magistral prescriptions or finished preparations for external therapy:
- Acetylsalicylic acid
- Ammonium bituminosulfonate
- Anthrarobin
- basic bismuth gallate
- Chlorocresol (negative benefit-risk assessment by the commission B7 of the former BGA!)
- Chlorquinaldol
- Ciclopiroxolamine
- Clioquinol
- Diclofenac-Na
- Dithranol
- Eosin-Na
- Estradiol
- Estriol
- 5-fluorouracil
- Glycolic acid
- Heparin-Na
- Hexachlorophen (negative benefit-risk assessment by the commission B7 of the former BGA!)
- hyaluronic acid
- Hydroquinone
- Potassium canrenoate
- coal tar solution and coal spirit
- Merbromine Na
- 2-naphthol (negative benefit-risk assessment by the commission B7 of the former BGA!)
- Phenolum liquefactum (negative benefit-risk assessment by the commission B7 of the former BGA!)
- Polyvidone-iodine
- Resorcinol (negative benefit-risk assessment by the B7 commission of the former BGA!)
- salicylic acid
- Tannin
- Thymol
- Tioxolone
- Tribromophenol bismuth (negative benefit-risk assessment by the B7 commission of the former BGA!)
- Triclosan
- Overview of the phenolic and phenolic-containing active ingredients used in magistral formulations or finished preparations for external therapy:
- Anthrarobin
- Chlorocresol (negative benefit-risk assessment by the commission B7 of the former BGA!)
- 2-Naphthol (negative benefit-risk assessment by the commission B7 of the former BGA!)
- Phenolum liquefactum (negative benefit-risk assessment by the commission B7 of the former BGA!)
- Pix betulina
- pix lithanthracis
- Resorcinol (negative benefit-risk assessment by the B7 commission of the former BGA!)
- salicylic acid
- Tannin
- Triclosan
Tables
This section has been translated automatically.
Overview of the active ingredients used in magistral formulations or finished preparations for external therapy and their maximum concentrations
Active ingredients |
Maximum concentration |
Remarks |
Aciclovir |
5% |
|
alclometasone 17,21-dipropionate |
0,5% |
|
Acriflavinium chloride |
2% |
obsolete! |
Allantoin |
0,2-3% |
|
Allethrin I |
0,6% |
|
Aluminium acetate, basic |
1,5-10% |
|
Aluminium chloride hexahydrate |
10-25% |
|
Amcinonide |
0,1% |
|
Ammonium bituminosulfonate (Ichthyol) |
10-50% |
|
Amorolfine hydrochloride |
0,25-5% |
|
amphotericin B |
3% |
|
Anthrarobin |
3% |
Problems with the pharmaceutical stability of the substance! |
Azelaic acid |
15-20% |
|
Azulen |
0,2% |
no longer used in dermatics! |
Bacitracin |
500 IU/g |
|
Bamipine HCl |
2% |
|
Benzalkonium chloride |
0,5% |
|
Benzoic acid |
6% |
obsolete! |
Benzocaine |
5-10% |
|
Benzoyl peroxide |
3-10% |
|
Benzyl alcohol |
2-5% |
|
Benzyl benzoate |
10-25% |
|
betamethasone 17-valerate |
0,15 |
|
betamethasone 17,21-dipropionate |
0,1 |
|
betamethasone 17-benzoate |
0,025% |
no longer used in Germany! |
Bifonazole |
1% |
|
Brilliant green |
0,5% |
unclear benefit-risk assessment; contaminated with heavy metals! |
Bufexamac |
5% |
|
Calcipotriol |
0,005% |
|
Calcium Chloride |
5% |
|
Capsaicin |
1% |
(0.05% according to NRF) |
Cetylpyridinium chloride x 2 H2O |
1,0% |
|
Cetylpyridinium chloride x 6 H2O |
2,0% |
|
Chloramine T |
0,25-10% |
|
Chloramphenicol |
2% |
|
Chlorhexidine digluconate |
1% |
|
Chlorocresol |
0,2-1,5% |
obsolete! |
Chlorphenoxamine-HCl |
1,5% |
|
Chlorquinaldol |
3% |
in Germany not used in dermatics! |
Chlortetracycline-HCl |
3% |
|
Chrysarobin |
5% |
obsolete! |
Ciclopiroxolamine |
1% |
|
Ciclosporin |
2% |
|
Clemastine fumarate |
0,04% |
|
clindamycin-2-dihydrogen phosphate |
1,2% |
|
Clioquinol |
3% |
|
clobetasol-17-propionate |
0,05% |
|
Clobetasone butyrate |
0,05% |
|
clocortolone-21-acetate |
0,03-0,1% |
no longer used in Germany! |
Clocortolone-21-hexanoate (= Clocortolone-21-caproate) |
0,03-0,1% |
no longer used in Germany! |
clocortolone-21-pivalate |
0,03-0,1% |
in Germany no longer used in dermatics! |
Clotrimazole |
1% |
|
Croconazole-HCl |
1% |
|
Crotamiton |
5-10% |
|
Dequalinium chloride |
0,4% |
|
Dequalinium salicylate |
1% |
not used in Germany! |
deoximetic acid |
0,25% |
|
Dexamethasone |
0,1% |
|
Dexpanthenol |
5% |
|
Dextranomer |
64% |
not used in Germany! |
diflorasone-17,21-acetate |
0,05% |
|
diflucortolone-21-valerate |
0,1-0,3% |
|
Dimeticon |
10% |
|
Dimetine maleate |
0,1% |
|
Diphenhydramine HCl |
2% |
|
Dithranol |
0,1-3,0% |
|
Econazole |
1% |
not used in dermatics! |
Econazole Nitrate |
1% |
|
Erythromycin |
4% |
|
Estradiol |
0,1% |
(0.015% according to NRF) |
Estriol |
0,1% |
|
Ethacridine lactate |
1% |
|
Eucalyptol |
10% |
|
Fenticonazole nitrate |
2% |
|
flumetasone-21-pivalate |
0,02% |
|
Fluocinoline acetonide |
0,025% |
|
Fluocortolone-21-hexanoate (= Fluocortolone-21-caproate) |
0,25% |
|
Fluorouracil |
5% |
|
fluprednide-21-acetate |
0,1% |
|
Fluticasone propionate |
0,05% |
|
Fomocaine HCl |
4% |
|
Foscarnet Sodium |
2% |
|
Framycetin sulfate |
2% |
|
Fusidic acid |
2% |
|
Gentamicin sulphate |
0,2% |
Reserve antibiotic! |
Griseofulvin |
5% |
|
Halometason |
0,05% |
|
Urea |
10-40% |
|
Hexachlorophen |
1-3% |
|
Hydrargyrum sulf. rubr. |
10% |
obsolete! negative evaluation of mercury compounds! |
hydrocortisone |
1% |
|
Hydrocortisone aceponate |
0,127% |
|
hydrocortisone 17-butyrate |
0,1% |
|
hydrocortisone 21-acetate |
1% |
|
Hydrocortisone buteprate |
0,1% |
|
hydrocortisone 21-butyrate |
0,1% |
|
Hydroxyquinoline sulfate |
1% |
|
Idoxuridine |
0,2% |
|
Isoconazole |
1% |
not used in dermatics! |
Isoconazole Nitrate |
1% |
|
Isotretinoin |
0,1% |
|
Potassium iodide |
35% |
|
Ketoconazole |
2% |
|
Lidocaine HCl |
5% |
|
Liq. alum. acet. |
10-20% |
|
Liquor carbonis detergens |
10% |
(20% according to NRF) |
meclocycline-5-sulfosalicylate |
1,5% |
|
Menthol |
0,1-10% |
|
Merbromine |
2% |
in Germany no longer used in dermatics! |
Methylprednisolone |
0,25% |
|
Methylprednisolone aceponate |
0,1% |
|
methyl salicylate |
4-50% |
|
Metronidazole |
2% |
(3% according to NRF) |
Miconazole Nitrate |
2% |
|
Lactic acid |
5% |
|
Miltefosine |
6% |
|
Mometason-17-(2-fuorat) |
0,1% |
|
Mupirocin-Calcium |
2,15% |
|
Naftifin-HCl |
1% |
|
Natamycin |
2% |
|
Sodium bituminosulfonate |
10% |
|
Sodium chloride |
10% |
|
Neomycin sulfate |
0,5% |
|
Benzyl nicotinate |
0,3-10% |
|
Nitrofurazone |
0,2% |
|
Nystatin |
100 000 IU/g |
|
Omoconazole nitrate |
1% |
in Germany there is no dermatological product with this active ingredient on the market anymore! |
oxiconazole nitrate |
1,15% |
|
Oxytetracycline-HCl |
3% |
|
Peru Balsam |
10% |
allergenic! obsolete! |
Pheniramine hydrogen maleate |
1,25% |
in Germany no longer used in dermatics! |
Phenolum liquefactum |
1% |
must no longer be applied to the skin or oral mucosa! |
Piperonyl butoxide |
3% |
|
pix betulinae |
5% |
|
pix juniperi |
5% |
|
pix lithanthracis |
10% |
|
Polidocanol |
8% |
|
polymyxin B |
0,2% |
|
Polyvidon Iodine |
10% |
|
Prednicarbate |
0,25% |
|
Prednisolone |
0,25-0,5% |
|
Prednisolone acetate |
0,5% |
|
Procaine HCl |
2% |
|
Pyrogallol |
2% |
|
Quinisocaine |
0,5% |
|
Resorcin |
5% |
negative benefit-risk assessment! should no longer be prescribed! |
Salicylic acid |
10% |
|
Sulphur |
10% |
|
Selenium disulfide |
2,5% |
|
Sertaconazole Nitrate |
2% |
|
Silver nitrate |
10% |
|
Sorbic acid |
0,1% |
|
Sulfadiazine Silver |
1% |
|
Sulphisomidine |
5% |
negative benefit-risk assessment due to sensitization! |
Tannin |
20% |
|
Terbinafine HCl |
1% |
|
Testosterone propionate |
2% |
|
Tetracaine HCl |
0,5% |
|
Tetracycline-HCl |
3% |
|
Thymol |
2% |
|
Tiabendazole |
10% |
|
Tioconazole |
1% |
|
Tobramycin |
0,3% |
|
Tolciclat |
1% |
|
Tolnaftat |
1% |
|
Tretinoin |
0,1% |
|
triamcinolone acetonide |
0,1% |
|
Trifluridine |
2% |
|
Tromantadine HCl |
1% |
|
Tyrothricin |
0,1% |
|
Undecylenic acid |
2% |
|
Vidarabin |
3% |
|
Zinc oxide |
25% |
|
Zinc undecylenate |
10% |
Active substance |
Optimum stability (pH value) |
Remarks |
Aluminium chloride hexahydrate |
2,3-3,5 |
|
Betamethasone dipropionate |
4 |
light sensitive |
betamethasone 17-valerate |
3,5 |
first isomerisation, then hydrolysis of the ester |
Chloramphenicol |
7,4 |
in borate buffer |
2-7 |
only 30 days stable at room temperature |
|
Chlorhexidine digluconate |
5-8 |
Optimum effect: pH 8 |
Clindamycin dihydrogen phosphate |
3,5-6,5 |
|
Clioquinol (e.g. Vioform) |
weakly acidic |
sensitive to light and moisture |
clobetasol-17-propionate |
4-6 |
Hydrolysis |
Clotrimazole |
7-8 |
Hydrolysis at pH < 5 |
dexamethasone |
3,5 |
side chains at alkaline pH; sensitive to oxidation |
Dexpanthenol |
3-7 |
|
Dithranol (e.g. cignoline) |
weakly acidic |
sensitive to oxidation: oxidation protection with salicylic acid required |
Erythromycin |
8,5 |
Decomposition at acidic pH values within a few hours |
Ethacridine-lactate (e.g. Rivanol) |
|
light sensitive |
Gentamicin sulfate |
2-14 |
in buffer solutions; optimum effect at pH 7.8 |
Urea |
6,2 |
Add lactate buffer from the NRF |
Hexachlorophen * |
5-6 |
bactericidal; bacteriostatic at pH 8 |
Hydrocortisone |
6-7 |
photostable in the presence of metal ions, oxygen and light |
Hydrocortisone acetate |
4,5 |
photostable in the presence of metal ions, oxygen and light; hydrolysis of the ester |
Metronidazole |
5 |
|
Nystatin |
5-7 |
light-sensitive; aqueous solution can be kept in the refrigerator for 1 week |
Oxytetracycline-HCl |
2 |
Optimum effect: pH 5.5-6.5 |
Prednisolone |
6-7 |
physically unstable: crystal formation in water-rich media; photostable: UV light (ring A) |
Prednisolone acetate |
4,5 |
Hydrolysis of the ester |
Resorcin * |
|
unstable when exposed to light and air; stabilizers in ointments are e.g. ascorbic acid and α-tocopherol |
Tetracaine HCl |
3-4-6 |
|
Tetracycline-HCl |
|
Optimum effect: pH 6.1-6.6; in water-containing vehicles, can be kept in the refrigerator for 7 days |
Tretinoin |
5 |
unstable when exposed to light and air; antioxidant addition required; crystallinity |
Triamcinolone acetonide |
7 |
Ketal residue of the compound is cleavable by acids |
Triclosan |
5 |
effective in the range pH 4-8; bactericidal effective at pH 5 (optimum effect!); bacteriostatic effective at pH 8 |
vitamin A palmitate |
4-6 |
more stable than acetate |